
#+OPTIONS:   H:4 toc:t num:2
#+PROPERTY:  padline no
#+SETUPFILE: ../bigblow-pirilampo.setup
#+LATEX_HEADER:\usepackage{amsmath}
#+LATEX_HEADER: \newcommand{\md}{\mathrm{d}}
#+TITLE: Model Fit





* Model Parameters
  We will estimate three parameters: the transmission probability from
  humans to tsetse $\beta_{VH}$, the transmission probability from
  tsetse to humans $\beta_H$ and rate of seeking treatment for stage
  II patients $\zeta_2$. The rest of parameters will either be fixed
  or be sampled from their distribution ($\eta$,$gamma_{H_i}$, and $P_{i+/D}$.)
   + */Tsetse/*


     | Parameter    | Definition                                 | Value           | Distribution | Reference        | To be estimated ? |
     |--------------+--------------------------------------------+-----------------+--------------+------------------+-------------------|
     | $1/\eta$     | Duration of pupae stage in tsetse          |                 | $20-40 ~d$   | [[https://paperpile.com/shared/c3Tolh][Rock et al. 2015]] |                   |
     | $B_V$        | Tsetse constant birth rate                 | $0.05 ~d^{-1}$  |              | [[https://paperpile.com/shared/YCjv50][Rogers 1988]]      |                   |
     | $\mu_{V_0}$  | Tsetse death rate without competition      | $0.025 ~d^{-1}$ |              | [[https://paperpile.com/shared/YCjv50][Rogers 1988]]      |                   |
     | $\mu_{V_1}$  | Death rate competition parameter           | $0.0002$        |              | Assumed          |                   |
     | $1/\sigma_V$ | Susceptibility period in tsetse            | $1 ~d$          |              | [[https://paperpile.com/shared/YCjv50][Rogers 1988]]      |                   |
     | $a_H$        | Tsetse human biting rate                   | $0.075 ~d^{-1}$ |              | [[https://paperpile.com/shared/YCjv50][Rogers 1988]]      |                   |
     | $\beta_{VH}$ | Trans. prob. from humans to tsetse         | $0.065$         |              | [[https://paperpile.com/shared/YCjv50][Rogers 1988]]      | Yes               |
     | $1/\tau_V$   | Incubation period in tsetse                | $25 ~d$         |              | [[https://paperpile.com/shared/YCjv50][Rogers 1988]]      |                   |
     | V            | Tsetse population size (carrying capacity) | $5000$          |              | Assumed          |                   |

   + */Human/*

     | Parameter        | Definition                                    | Value         | Distribution   | Reference           | To be estimated ? |
     |------------------+-----------------------------------------------+---------------+----------------+---------------------+-------------------|
     | $\mu_H$          | Human constant death rate                     | $1/55~y^{-1}$ |                | Google (to update)  |                   |
     | $\beta_H$        | Trans. prob. from tsetse to humans            | $0.62$        |                | [[https://paperpile.com/shared/YCjv50][Rogers 1988]]         |      Yes          |
     | $1/\tau_H$       | Incubation period in humans                   | $12 ~d$       |                | [[https://paperpile.com/shared/YCjv50][Rogers 1988]]         |                   |
     | $1/\gamma_{H_1}$ | Stage I infectious period without treatment   |               | $0.98-2.28 ~y$ | [[https://paperpile.com/shared/jz7HRk][Checchi et al. 2008]] |                   |
     | $1/\gamma_{H_2}$ | Stage II infectious period  without treatment |               | $0.95-2.11 ~y$ | [[https://paperpile.com/shared/jz7HRk][Checchi et al. 2008]] |                   |
     | H                | Human population size                         | $300$         |                | Assumed             |                   |


   + */Treatment/*

     | Parameter    | Definition                                                                                              | Value   | Distribution | Reference                   | To be estimated ? |
     |--------------+---------------------------------------------------------------------------------------------------------+---------+-------------+-----------------------------+-------------------|
     | $P_1$        | Probability a stage I individual gets a CATT test                                                       | $0$     |             |                             |                   |
     | $P_{1+/D}$   | Probability a stage I individual gets a positive CATT and positive parasitology test                    |         | $0.87-0.98$ | [[https://paperpile.com/shared/ea9YR0][Brun et al. 2010]]            |                   |
     | $P_{1T/+}$   | Probability a stage I individual gets treated upon getting positive CATT and positive parasitology test | $1$     |             | Data                        |                   |
     | $P_2$        | Probability a stage I individual gets a CATT test                                                       | $1$     |             |                             |                   |
     | $P_{2+/D}$   | Probability a stage I individual gets a positive CATT and positive parasitology test                    |         | $0.87-0.98$ | [[https://paperpile.com/shared/ea9YR0][Brun et al. 2010]]            |                   |
     | $P_{2T/+}$   | Probability a stage I individual gets treated upon getting positive CATT and positive parasitology test | $1$     |             | Data                        |                   |
     | $\epsilon_1$ | Efficacy of stage I treatment (pentamidine)                                                             | $0.94$  |             | [[https://paperpile.com/shared/mTj51B][Doua et al. 1996]]            |                   |
     | $\epsilon_2$ | Efficacy of stage II treatment (nifurtimox-eflornithine)                                                | $0.965$ |             | [[https://paperpile.com/shared/cTV6IV][Priotto et al. 2009]]         |                   |
     | $1/\zeta_1$  | Treatment period for stage I patients                                                                   |         |             | Does not matter for fitting |                   |
     | $1/\zeta_2$  | Treatment period for stage II patients                                                                  |         |             |                             |  Yes              |
     | $p_2$        | Probability of death due to stage II treatment failure (nifurtimox-eflornithine)                        | $0.007$ |             | [[https://paperpile.com/shared/cTV6IV][Priotto et al. 2009]]         |                   |
     | $1/\delta_H$ | Immune period in Humans after treatment                                                                 | $50 ~d$ |             | [[https://paperpile.com/shared/YCjv50][Rogers 1988]]                 |                   |



* Priors
  | Parameter    | Prior         |
  |--------------+---------------|
  | $\beta_{VH}$ | $U(0,\infty)$ |
  | $\beta_{H}$  | $U(0,\infty)$ |
  | $1/\zeta_2$  | $U(0,\infty)$ |


* Likelihood
